Cantor Fitzgerald Predicts Increased Earnings for AbbVie

Key Points

• Cantor Fitzgerald has revised AbbVie's FY2025 earnings per share (EPS) estimate upward to $12.05, and estimates FY2026 EPS at $14.35, maintaining an "Overweight" rating with a price target of $210.00.
• Other analysts, including Guggenheim and Daiwa America, have also raised their price targets and ratings for AbbVie, with the consensus rating currently at "Moderate Buy" and an average target price of $214.95.
• AbbVie recently declared a quarterly dividend of $1.64 per share, representing an annualized dividend yield of 3.2%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a research report issued to clients and investors on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now expects that the company will post earnings per share of $12.05 for the year, up from their previous forecast of $11.84. Cantor Fitzgerald currently has a "Overweight" rating and a $210.00 price target on the stock. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Cantor Fitzgerald also issued estimates for AbbVie's FY2026 earnings at $14.35 EPS.

Other research analysts have also issued reports about the company. Guggenheim raised their target price on AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Daiwa America raised AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. BNP Paribas raised AbbVie to a "hold" rating in a research report on Thursday, May 8th. Daiwa Capital Markets raised AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 price objective for the company in a research report on Thursday, August 7th. Finally, Piper Sandler initiated coverage on AbbVie in a research report on Tuesday. They issued an "overweight" rating and a $231.00 price objective for the company. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and five have given a strong buy rating to the stock. According to MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and an average target price of $214.95.

AbbVie Trading Up 0.4%

NYSE:ABBV traded up $0.89 during trading hours on Friday, hitting $205.57. 1,033,284 shares of the company were exchanged, compared to its average volume of 6,687,781. The stock has a market capitalization of $363.15 billion, a price-to-earnings ratio of 97.89, a price-to-earnings-growth ratio of 1.29 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie has a one year low of $163.81 and a one year high of $218.66. The company has a fifty day simple moving average of $190.74 and a 200 day simple moving average of $191.86.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business earned $2.65 EPS.

Institutional Investors Weigh In On AbbVie

A number of institutional investors have recently made changes to their positions in the stock. TD Capital Management LLC grew its holdings in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after acquiring an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the 2nd quarter valued at $25,000. Abound Financial LLC purchased a new stake in AbbVie in the 1st quarter valued at $30,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the 2nd quarter valued at $28,000. Finally, Cypress Capital Management LLC WY acquired a new position in AbbVie in the 1st quarter valued at $35,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares in the company, valued at $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by company insiders.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be given a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.2%. The ex-dividend date is Tuesday, July 15th. AbbVie's dividend payout ratio (DPR) is currently 312.38%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.